ATA137799A - Faktor x-analogon mit verbesserter aktivierbarkeit - Google Patents

Faktor x-analogon mit verbesserter aktivierbarkeit

Info

Publication number
ATA137799A
ATA137799A AT0137799A AT137799A ATA137799A AT A137799 A ATA137799 A AT A137799A AT 0137799 A AT0137799 A AT 0137799A AT 137799 A AT137799 A AT 137799A AT A137799 A ATA137799 A AT A137799A
Authority
AT
Austria
Prior art keywords
analog
factor
improved activation
analog factor
amino acid
Prior art date
Application number
AT0137799A
Other languages
English (en)
Other versions
AT410216B (de
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Priority to AT0137799A priority Critical patent/AT410216B/de
Priority to US09/632,722 priority patent/US6958322B1/en
Priority to AU62807/00A priority patent/AU778571B2/en
Priority to DE60038312T priority patent/DE60038312T2/de
Priority to DK00949465T priority patent/DK1238065T3/da
Priority to ES00949465T priority patent/ES2302696T3/es
Priority to PCT/EP2000/007631 priority patent/WO2001010896A2/en
Priority to AT00949465T priority patent/ATE389013T1/de
Priority to CA002380844A priority patent/CA2380844A1/en
Priority to EP00949465A priority patent/EP1238065B1/de
Publication of ATA137799A publication Critical patent/ATA137799A/de
Application granted granted Critical
Publication of AT410216B publication Critical patent/AT410216B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT0137799A 1999-08-10 1999-08-10 Faktor x-analogon mit verbesserter aktivierbarkeit AT410216B (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AT0137799A AT410216B (de) 1999-08-10 1999-08-10 Faktor x-analogon mit verbesserter aktivierbarkeit
US09/632,722 US6958322B1 (en) 1999-08-10 2000-08-04 Factor X analog with an improved ability to be activated
DE60038312T DE60038312T2 (de) 1999-08-10 2000-08-07 Faktor x-analog mit einer verbesserten fähigkeit, aktiviert zu werden
DK00949465T DK1238065T3 (da) 1999-08-10 2000-08-07 Faktor X-analog med forbedret evne til aktivering
AU62807/00A AU778571B2 (en) 1999-08-10 2000-08-07 Factor X analog with an improved ability to be activated
ES00949465T ES2302696T3 (es) 1999-08-10 2000-08-07 Analogo de factor x con mejor capacidad de activacion.
PCT/EP2000/007631 WO2001010896A2 (en) 1999-08-10 2000-08-07 Factor x analog with an improved ability to be activated
AT00949465T ATE389013T1 (de) 1999-08-10 2000-08-07 Faktor x-analoge mit verbesserter fähigkeit zur aktivierung
CA002380844A CA2380844A1 (en) 1999-08-10 2000-08-07 Factor x analog with an improved ability to be activated
EP00949465A EP1238065B1 (de) 1999-08-10 2000-08-07 Faktor x-analoge mit verbesserter fähigkeit zur aktivierung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0137799A AT410216B (de) 1999-08-10 1999-08-10 Faktor x-analogon mit verbesserter aktivierbarkeit

Publications (2)

Publication Number Publication Date
ATA137799A true ATA137799A (de) 2002-07-15
AT410216B AT410216B (de) 2003-03-25

Family

ID=3512576

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0137799A AT410216B (de) 1999-08-10 1999-08-10 Faktor x-analogon mit verbesserter aktivierbarkeit
AT00949465T ATE389013T1 (de) 1999-08-10 2000-08-07 Faktor x-analoge mit verbesserter fähigkeit zur aktivierung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00949465T ATE389013T1 (de) 1999-08-10 2000-08-07 Faktor x-analoge mit verbesserter fähigkeit zur aktivierung

Country Status (9)

Country Link
US (1) US6958322B1 (de)
EP (1) EP1238065B1 (de)
AT (2) AT410216B (de)
AU (1) AU778571B2 (de)
CA (1) CA2380844A1 (de)
DE (1) DE60038312T2 (de)
DK (1) DK1238065T3 (de)
ES (1) ES2302696T3 (de)
WO (1) WO2001010896A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
WO2006018204A1 (en) * 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
EP1728798A1 (de) 2005-06-01 2006-12-06 ZLB Behring GmbH Blutgerinnungsfaktor X Polypeptide mit veränderten Aktivierungseigenschaften
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (de) * 2006-02-21 2007-08-22 CSL Behring GmbH Polypeptide des Gerinnfaktors X mit geänderten Aktivierungseigenschaften
WO2008141824A2 (en) 2007-05-22 2008-11-27 Baxter International Inc. Preparative purification process for human furin
EP2235188A2 (de) * 2007-12-31 2010-10-06 Baxter International Inc. Expression von humanen blutgerinnungsfaktoren bei transgenen nichthumanen tieren
AU2010279463A1 (en) * 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
EP3049434A1 (de) 2013-09-24 2016-08-03 Pfizer Inc. Zusammensetzungen mit heterogenen populationen aus rekombinanten menschlichen proteinen mit dem gerinnungsfaktor xa
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
FR3050992A1 (fr) * 2016-05-06 2017-11-10 Lab Francais Du Fractionnement Mutants du facteur x

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT366916B (de) 1980-04-02 1982-05-25 Immuno Ag Vorrichtung zur applikation eines gewebeklebstoffes auf basis von menschlichen oder tierischenproteinen
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
AT382783B (de) 1985-06-20 1987-04-10 Immuno Ag Vorrichtung zur applikation eines gewebeklebstoffes
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
DE4325872C1 (de) 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
AT404838B (de) 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle

Also Published As

Publication number Publication date
WO2001010896A2 (en) 2001-02-15
DE60038312T2 (de) 2009-03-26
DK1238065T3 (da) 2008-07-07
AU6280700A (en) 2001-03-05
ES2302696T3 (es) 2008-08-01
WO2001010896A3 (en) 2002-07-11
EP1238065B1 (de) 2008-03-12
CA2380844A1 (en) 2001-02-15
AT410216B (de) 2003-03-25
DE60038312D1 (de) 2008-04-24
AU778571B2 (en) 2004-12-09
ATE389013T1 (de) 2008-03-15
EP1238065A2 (de) 2002-09-11
US6958322B1 (en) 2005-10-25

Similar Documents

Publication Publication Date Title
ATA137799A (de) Faktor x-analogon mit verbesserter aktivierbarkeit
ATE310009T1 (de) Reaktionssysteme zur herstellung von n- (phosphonomethyl)glyzin verbindungen
DE60017336D1 (de) Zusammensetzung zur Herstellung von Harzen
DE60114002D1 (de) VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION
DE60108042D1 (de) Prozesse zur Herstellung von pulverförmigen Schlagzäh-Modifizierern
DE69909003D1 (de) Verfahren zur Herstellung von Polyamiden
DE69938535D1 (de) Dampfphasenprozess zur Herstellung von Aluminid
EP0588351A3 (de) Harte, gegen Verschleiss widerstandsfähige Beschichtung und Verfahren zur Herstellung derselben.
DE60032894D1 (de) Verfahren zur herstellung von stadtgas
DE59709869D1 (de) Neue substanzbibliothek und damit hergestellte supramolekulare komplexe
DE60100217D1 (de) Verfahren zur Herstellung von hochkonzentrierten Kohlendioxid
MXPA02004829A (es) Metodo para la sintesis estereoselectiva de aminoacidos ciclicos.
DE60002254D1 (de) Verfahren zur Herstellung von 4,6-diaminoresorcin
DE69822711D1 (de) Verfarhen zur Herstellung von Dialkylnaphthalinen
DE59506870D1 (de) Verfahren zur Herstellung von Polyamiden auf Basis von alpha,omega-Dinitrilen
DE19983485T1 (de) Verfahren zur Herstellung von Gasfedern
DE69104816D1 (de) Verfahren zur Herstellung von Ammoniak-Synthesegas.
DE69812438T2 (de) Zusammensetzung zur herstellung von brennstoff-briketts
DE60103560D1 (de) Prozess zur herstellung von paclitaxel
DE69924026D1 (de) Coenzym zur herstellung von l-carnitin
ATE242763T1 (de) Methoximinophenylessigsäureamide
DE60043559D1 (de) Verfahren zur Herstellung von Elektroden
PT1246790E (pt) Bases de mannich de 1- e 2-naftol substituido
JP2000186092A5 (de)
ATE331733T1 (de) Metallhaltige ribonukleotidpolypeptide

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee